Abstract: In a screening test method, and a device for implementing the screening test method, a diagnostic substance is provided that contains at least one biomarker connected with at least one ferromagnetic particle, the biomarker binding specifically to a target molecule that is formed by specific pathological prostrate tissue. The diagnostic substance is administered to the blood stream of a patient. A magnetometer is used to detect enrichment of the ferromagnetic particle in the prostrate, as an indicator of a level of the specific pathological prostrate tissue.

Abstract: The invention relates to a method and to an apparatus for recognizing tumorous living cell tissue. It furthermore relates to a method and to an apparatus for recognizing tumorous cell tissue at collected living cell tissue samples. In the method, electromagnetic radiation is emitted with local definition onto cell tissue by a radiation source and, after deactivation of the radiation source, the decay behavior of the inherent fluorescence intensity of the cell tissue excited by the electromagnetic radiation is detected at the cell tissue in a time resolved and spectrally resolved manner at known sampling rate(s) for at least one wavelength using a detector.

Abstract: In a method for treating a carcinoma in a patient, a medicine is administered via the blood stream of the patient that appears, to the patient's immune system, that tissue of the carcinoma is an inflammation source. The medicine employs two active components that are coupled to each other in a form allowing administration of the two active components to the carcinoma via the blood stream of the patient. A first of the active components is at least one coupling molecule that specifically tethers to a target molecule formed by cancer tissue of the carcinoma. A second of the active ingredients is at least one signal molecule typical to inflammation, or at least one originating molecule encoding such a signal molecule, that induces the immune system of the body to attack the cancer cells.

Abstract: In a method, a device and an apparatus system for therapy of prostate cancer, in the course of a therapy session the prostate of a patient is subjected at different locations to a diagnostic examination with regard to the presence of a tumor, and in the case of a positive diagnosis the prostate is therapeutically treated at the corresponding location during the therapy session. The device has a hollow needle, a biopsy needle carrying an extraction element at its forward end that serves to extract a tissue sample, and a therapy element serving to therapeutically act at a location of the prostate. The biopsy needle or the optical waveguide and the therapy element are designed so that they can be inserted into the hollow needle. The apparatus system includes a diagnostic unit and a therapy unit for focal therapy treatment of the prostate, the diagnostic unit including a device for histological assessment of prostate tissue.

Abstract: In a screening test method, and a device for implementing the screening test method, a diagnostic substance is provided that contains at least one biomarker connected with at least one ferromagnetic particle, the biomarker binding specifically to a target molecule that is formed by specific pathological prostrate tissue. The diagnostic substance is administered to the blood stream of a patient. A magnetometer is used to detect enrichment of the ferromagnetic particle in the prostrate, as an indicator of a level of the specific pathological prostrate tissue.

Abstract: In order to determine the aggressiveness of a prostate tumor, a diagnostic substance is administered to a patient that includes a biomarker provided with a first label that is detectable with a detection device and that specifically binds to a VEGF molecule, and that contains a biomarker that binds specifically to a target molecule that occurs uniformly in the endothelium of blood vessels of healthy tissue and the blood vessels of a prostate tumor, and that is provided with a second label that is detectable with the detection device independently of the first label.

Abstract: In a shockwave system with a shockwave source for treatment of a patient with shockwaves, a control and evaluation unit for evaluating an input signal supplied directly thereto that is correlated with a blood pressure value of the patient determined during the treatment, and controls the shockwave source dependent on the input signal.

Abstract: A urological x-ray workstation has an x-ray source and an x-ray receiver that are respectively supported on device retainers of a device carrier located at the longitudinal side of a patient positioning table such that they can be positioned opposite one another and independently of one another in various positions on an orbit proceeding around a common center in a working plane oriented perpendicular to the longitudinal axis.

Abstract: In a method for image guided prostate cancer needle biopsy, a first registration is performed to match a first image of a prostate to a second image of the prostate. Third images of the prostate are acquired and compounded into a three-dimensional (3D) image. The prostate in the compounded 3D image is segmented to show its border. A second registration and then a third registration different from the second registration is performed on distance maps generated from the prostate borders of the first image and the compounded 3D image, wherein the first and second registrations are based on a biomechanical property of the prostate. A region of interest in the first image is mapped to the compounded 3D image or a fourth image of the prostate acquired with the second modality.

Abstract: A diagnostic substance for use in a method for diagnosing prostate diseases contains multiple different coupling molecules that respectively bind to signal molecules (target molecules) of a molecular surface structure of a pathological tissue that is associated with a prostate disease. A first of the coupling molecules specifically binds to signal molecules of cancer tissue, and a second of the coupling molecules specifically binds to signal molecules formed in inflamed tissue. First and second markers are respectively associated with the first and second coupling molecules, the first and second markers being detectable, and differentiated from each other, with a detection device.

Abstract: In a method to determine at least one parameter pertaining to a prostate of a patient, an integrated diagnostic support system implements the following steps. A first risk value for prostate illness is determined using a screening method. In the event that this first characteristic risk value exceeds a first limit value, at least one second characteristic risk value for prostate illness and its location are determined using a method supplying a medical image of the patient. An integrated report system outputs at least one of the characteristic risk values and/or the location. A corresponding device has a mini-laboratory analysis unit for the screening test, an intelligent decision support system for the first characteristic risk value, a first interface with an imaging system, an evaluation system for the medical image for the second characteristic risk value, and a report system with a user interface.

Abstract: A urological x-ray workstation has an x-ray source and an x-ray receiver that are respectively supported on device retainers of a device carrier located at the longitudinal side of a patient positioning table such that they can be positioned opposite one another and independently of one another in various positions on an orbit proceeding around a common center in a working plane oriented perpendicular to the longitudinal axis.

Abstract: In a method and a device for x-ray brachytherapy, a probe is inserted into the interior of the body of a subject, the probe carrying at its distal end an x-ray source that radiates x-rays into an exposure area in the body of the subject outside of the probe. The probe also contains an x-ray array that generates an ultrasound image representing at least a portion of the exposure area. A display device displays the ultrasound image to allow identification of the exposure area in the ultrasound image.

Abstract: In a method to generate a three-dimensional ultrasound image of a body region of a patient, spatially varying due to breathing motions, temporally successive B-images are generated with an ultrasonic transducer arrangement in a stationary image plane that, due to the breathing motion, pertain to various slice planes of the body region, and are combined dimensionally correctly with an image processing device into a 3D image.

Abstract: The invention concerns a medicine for treatment of prostate cancer and a corresponding treatment method. The medicine can be supplied to a prostate tumor through the bloodstream, contains an active component and a binding component as well as ultrasound microbubbles. The binding component includes coupling molecules that specifically bind to a determined target molecule formed in the endothelium of tumor-associated blood vessels and that is typical of the tumor or the tumor stage. The active component contains at least one chemotherapeutic substance. The coupling molecules are bound to the outside of the microbubbles and active substance molecules are likewise bound to the outside of the microbubbles or are enclosed by the microbubbles.

Abstract: In a method for diagnosis and treatment of a patient with regard to prostatitis, a differential diagnosis of prostatitis versus prostate cancer and/or BPH is conducted on a patient using a cost-effective diagnosis method. Given diagnosed prostatitis, a cost-effective decision test is implemented on the patient to determine whether the patient exhibits complaints locally in the region of the prostate or in the rest of the body. A molecular inflammation marker is administered to the patient, wherein a cost-effective imaging method is implemented in the region of the prostate of the patient given local complaints or a cost-intensive imaging method is implemented on the entire patient given complaints in the rest of the body. An inflammation-inhibiting treatment is implemented in the body region of the patient that is detected as inflamed via the respective imaging method.

Abstract: A contrast agent for ultrasound examination of the prostate has contrast-intensifying particles on an exterior of which at least one binding molecule is present that specifically binds to CEACAM-1. In a method for ultrasound examination of the prostate, such a contrast agent is administered to the patient and a sonography of the prostate is subsequently implemented.

Abstract: In a method for imaging a prostate tumor in which a contrast agent that can be distributed via the circulatory system is administered to the patient, the contrast agent contains at least one type of biomarkers which are bound to a ferromagnetic particle and specifically bind to a target molecule typical of the tumor and formed within the tumor or in a tissue adjacent to the tumor. The imaging ensues with the use of magnetic resonance tomography.

Abstract: A diagnosis substance for application in a method for diagnosis of pathological tissue, contains at least one virus population with virus particles specifically binding to target molecules typical of a specific pathological tissue, with a label that is detectable with the use of a detection device being bound to the virus particles. In a method for production of such a diagnosis substance, the principle of directed biological evolution is applied.

Abstract: A medicine for treatment of a carcinoma which can be supplied to the carcinoma via the circulatory system, contains two active components coupled to one another. The first active component is formed of at least one coupling molecule that specifically tethers to a target molecule formed by the cancer tissue. The second active component is formed of at least one signal molecule typical to inflammation, or of at least originating molecule encoding such a signal molecule.